Target Binding Site Detail
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T80526 | Target Info | |||
| Target Name | Casein kinase II alpha prime (CSNK2A2) | ||||
| Synonyms | Casein kinase II subunit alpha'; CK2A2; CK II alpha' | ||||
| Target Type | Patented-recorded Target | ||||
| Gene Name | CSNK2A2 | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Ligand General Information | Top | ||||
|---|---|---|---|---|---|
| Ligand Name | Vitamin B3 | Ligand Info | |||
| Canonical SMILES | C1=CC(=CN=C1)C(=O)O | ||||
| InChI | 1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9) | ||||
| InChIKey | PVNIIMVLHYAWGP-UHFFFAOYSA-N | ||||
| PubChem Compound ID | 938 | ||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| PDB ID: 5YF9 Crystal structure of CK2a2 form-2 | ||||||
| Method | X-ray diffraction | Resolution | 1.89 Å | Mutation | No | [1] |
| PDB Sequence |
AGSRARVYAE
15 VNSLRSREYW25 DYEAHVPSWG35 NQDDYQLVRK45 LGEVFEAINI60 TNNERVVVKI 70 LKPVKKKKIK80 REVKILENLR90 GGTNIIKLID100 TVKDPVSKTP110 ALVFEYINNT 120 DFKQLYQILT130 DFDIRFYMYE140 LLKALDYCHS150 KGIMHRDVKP160 HNVMIDHQQK 170 KLRLIDWGLA180 EFYHPAQEYN190 VRVASRYFKG200 PELLVDYQMY210 DYSLDMWSLG 220 CMLASMIFRR230 EPFFHGQDNY240 DQLVRIAKVL250 GTEELYGYLK260 KYHIDLDPHF 270 NDILGQHSRK280 RWENFIHSEN290 RHLVSPEALD300 LLDKLLRYDH310 QQRLTAKEAM 320 EHPYFYPVV
|
|||||
|
|
||||||
| PDB ID: 5YWM Crystal structure of CK2a2 form-1 | ||||||
| Method | X-ray diffraction | Resolution | 1.94 Å | Mutation | No | [2] |
| PDB Sequence |
GSRARVYAEV
16 NSLRSREYWD26 YEAHVPSWGN36 QDDYQLVRKL46 GSEVFEAINI60 TNNERVVVKI 70 LKPVKKKKIK80 REVKILENLR90 GGTNIIKLID100 TVKDPVSKTP110 ALVFEYINNT 120 DFKQLYQILT130 DFDIRFYMYE140 LLKALDYCHS150 KGIMHRDVKP160 HNVMIDHQQK 170 KLRLIDWGLA180 EFYHPAQEYN190 VRVASRYFKG200 PELLVDYQMY210 DYSLDMWSLG 220 CMLASMIFRR230 EPFFHGQDNY240 DQLVRIAKVL250 GTEELYGYLK260 KYHIDLDLGQ 276 HSRKRWENFI286 HSENRHLVSP296 EALDLLDKLL306 RYDHQQRLTA316 KEAMEHPYFY 326 PVV
|
|||||
|
|
||||||
| PDB ID: 5Y9M Crystal structure of CK2a2 form 3 | ||||||
| Method | X-ray diffraction | Resolution | 2.01 Å | Mutation | No | [1] |
| PDB Sequence |
GSRARVYAEV
16 NSLRSREYWD26 YEAHVPSWGN36 QDDYQLVRKL46 GSEVFEAINI60 TNNERVVVKI 70 LKPVKKKKIK80 REVKILENLR90 GGTNIIKLID100 TVKDPVSKTP110 ALVFEYINNT 120 DFKQLYQILT130 DFDIRFYMYE140 LLKALDYCHS150 KGIMHRDVKP160 HNVMIDHQQK 170 KLRLIDWGLA180 EFYHPAQEYN190 VRVASRYFKG200 PELLVDYQMY210 DYSLDMWSLG 220 CMLASMIFRR230 EPFFHGQDNY240 DQLVRIAKVL250 GTEELYGYLK260 KYHIDLDPHF 270 NDILGQHSRK280 RWENFIHSEN290 RHLVSPEALD300 LLDKLLRYDH310 QQRLTAKEAM 320 EHPYFYPVV
|
|||||
|
|
||||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Crystal structures of human CK2Alpha2 in new crystal forms arising from a subtle difference in salt concentration. Acta Crystallogr F Struct Biol Commun. 2018 May 1;74(Pt 5):288-293. | ||||
| REF 2 | Crystal structure of human CK2a2 in a new crystal form at 1.89 angstrom resolution | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.